|
|
||||||||
Department of Cardiothoracic Surgery, Mount Sinai Medical Center, New York, New York
* Address correspondence to Dr Weiser, Department of Cardiothoracic Surgery, Mount Sinai Medical Center, 1190 Fifth Ave, Box 1028, New York, NY—10029 (Email: todd.weiser{at}mountsinai.org).
Presented at the Minimally Invasive Thoracic Surgery Summit, New York, NY, June 8–9, 2007.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
The least invasive of these procedures is flexible bronchoscopy, yet its value is often limited by the size and location of the lesion of interest. The diagnostic yield of fiberoptic bronchoscopy has been reported to range from 19% to 62% [2, 3]. Novel technologies have evolved that can improve the accuracy and expand the applicability of flexible bronchoscopy in rendering a tissue diagnosis for pulmonary nodules. One recent technical advance uses electromagnetic guidance to improve the ability of the bronchoscopist to navigate within the lung parenchyma as well as to localize and biopsy mediastinal pathology. This article will highlight the steps in planning and performing electromagnetic navigational bronchoscopy (ENB), review relevant literature on its use, and describe our experience with this diagnostic procedure.
Electromagnetic navigational bronchoscopy enables the guidance of bronchoscopic instruments to target areas within the lung parenchyma that often are beyond the view of standard fiberoptic bronchoscopy. Once directed to radiographic abnormalities, standard bronchoscopic forceps, histology needles, and cytologic brushes can be used to obtain tissue specimens. This technology can also be used to increase the diagnostic yield of transtracheal needle aspiration of mediastinal pathology. The ENB system (superDimension/Bronchus system; superDimension Inc, Plymouth, MN) consists of four essential components:
In addition to the diagnostic applications of ENB, an attractive therapeutic utility of this technology involves the bronchoscopic placement of fiducial markers with ENB guidance. These markers can facilitate treatment localization for stereotactic radiosurgery in patients with early-stage bronchogenic carcinoma who are otherwise unfit for surgical resection. This mode of external beam radiotherapy allows the administration of radiation from different paths to minimize damage to normal adjacent tissue. To date, most fiducial markers have been placed by using a CT-guided, transthoracic approach, but the associated rate of pneumothorax has been relatively high [4, 5]. This complication in these high-risk patients, who usually have significant respiratory insufficiency, could potentially lead to further deterioration of lung function.
| Technical Aspects of Electromagnetic Navigational Bronchoscopy |
|---|
|
|
|---|
|
After registration, the system can display the real-time location of the sensor probe within the patients thorax in relation to virtual endoscopic and CT images in sagittal, coronal, and axial views. The probe and EWC are then advanced beyond the vision of the bronchoscope to the lesion of interest by using real-time navigational techniques (Fig 2A, B). Once the target is reached, the EWC is locked in place, the locatable sensor is removed, and the bronchoscopic tools are advanced out to the lesion. Fluoroscopy can be used to verify accurate position of the locatable guide/EWC before the sensor is removed. Repeat fluoroscopy can verify that the EWC was not dislodged during placement of the diagnostic instruments through the EWC. In experienced hands, this last step may prove redundant [6, 7].
|
|
| Published Experience with Electromagnetic Navigational Bronchoscopy |
|---|
|
|
|---|
The overall success rate in obtaining diagnostic tissue in these ENB procedures was 80.3%. For peripheral lung lesions, diagnostic yield was 74%, and 31 of 31 lymph nodes sampled yielded a definitive diagnosis or benign lymphoid tissue. The results for positive yields were not significantly affected by location or lesion size. The mean ± SD sizes of lung and lymph node targets were 22.8 ± 12.6 mm and 28.1 ± 12.8 mm, respectively. The 11 patients whose pathologic results with ENB were nondiagnostic went on to have further diagnostic modalities performed that revealed malignant diagnoses. The imaging methods used were thoracotomy in 6 patients, CT-guided needle biopsy in 3, mediastinoscopy in 1, and positron emission tomography (PET) in 1. Postprocedural pneumothoraces occurred in 2 patients (3.5%), and both required tube thoracostomy.
Electromagnetic navigational bronchoscopy was performed by Eberhardt and colleagues [7], without fluoroscopic confirmation, to biopsy 92 peripheral pulmonary lesions in 89 patients. In this evaluation, the overall diagnostic yield was 67% and was independent of lesion size and lobar distribution. A definitive histologic diagnosis was obtained by using ENB in 52 lesions (57%). In 24 patients with 26 lesions, biopsy specimens were nondiagnostic and an alternative diagnosis was obtained with subsequent procedures. The remaining 14 lesions were monitored with serial imaging for a mean duration of 16.1 ± 1.8 months, and 10 of these were deemed as true-negative results on the basis of radiographic stability. Clearly, not having definitive histologic validation of the benign nature of these lesions was a weakness of that study. Total procedural time was from 16.3 to 45 minutes. Two pneumothoraces were encountered but required no intervention.
A recently published, prospective, randomized study sought to examine the value of combining ENB with endobronchial ultrasound (EBUS) in obtaining a diagnosis of peripheral lung lesions [9]. Patients were randomized to undergo ENB or EBUS alone, or combined ENB/EBUS procedures. This last group underwent navigation with the locatable sensor/EWC, and when it was close to the target, the sensor was removed and the EBUS probe was placed through the EWC to the lesion. Biopsies were performed in the combined modality group when EBUS confirmed the EWC was close to the target. Biopsy specimens in all groups were obtained by using forceps instruments only, and fluoroscopy was not used. A definitive histologic diagnosis was rendered in 118 of the 120 patients entered in the study, and they were included in the final analysis. The remaining 2 patients had a nondiagnostic bronchoscopic procedure and refused further biopsy.
The diagnostic yield from combined ENB/EBUS (88%) was significantly greater than that for ENB (59%) or EBUS (69%) alone. This significance was also seen in subset analysis for lesion size, lobar distribution, and malignant pathology. The overall incidence of iatrogenic pneumothorax was 6% and was not significantly different across the three groups. The authors attribute the enhanced yield with the sequential procedure to overcoming the deficiencies of one technology with the strength of the other: ENB allows the accurate, real-time navigation of the EBUS probe and the ultrasound component enables more effective visualization and confirms target location. Of importance in this particular study was that inconclusive histologic findings were all clarified with specimens from subsequent surgical biopsy. This was not performed in previous investigations with this technology.
Several reports are now emerging regarding ENB-guided placement of fiducial markers to facilitate stereotactic radiosurgery. Anantham and colleagues [10] reported their experience with placement of 39 fiducial markers in 9 patients. Deployment was deemed successful when at least 3 markers were close enough (<6 cm) to the tumor center when radiosurgical planning was performed 7 to 10 days after fiducial placement. The success rate for this study was 89% (8 of 9 patients). The failure was due to inability of the locatable guide to be navigated close to the tumor. The mean number of fiducial markers placed in each patient was 4.9 ± 1.0 (range, 4 to 6). At the time of radiosurgical planning, 35 of the 39 fiducial markers (90%) had not migrated. The only significant complication in the series occurred in 1 patient who sustained a chronic obstructive pulmonary disease exacerbation 1 day after the procedure.
A retrospective study was recently published documenting the stability of fiducial markers within the lung either placed through the transthoracic route (n = 15) or by ENB guidance (n = 8) [5]. All markers placed were suitable for use in image-guided radiotherapy and demonstrated no substantial migration within the lung. Of note, pneumothorax occurred in 7 of 15 patients (47%) who underwent transthoracic placement of the fiducial sustained, but none occurred in patients receiving the ENB placed markers.
| Our Clinical Experience With Electromagnetic Navigational Bronchoscopy |
|---|
|
|
|---|
|
Case 3 we considered a failure of this technology. A subcarinal lymph node aspiration failed to reveal sarcoidosis in a patient who underwent left thoracoscopy, under the same anesthetic, to sample mediastinal lymphadenopathy. This patient had previously sustained significant cutaneous burns and was deemed a poor candidate for cervical mediastinoscopy because of skin contractures.
Cases 4 and 5 revealed recurrent non-small cell carcinomas in hilar lymph nodes of patients who had undergone prior pulmonary lobectomies. A fiducial marker was placed in patient 5 to facilitate stereotactic radiosurgery, as described elsewhere [10].
Two of our four ENB-guided peripheral lung biopsies were deemed successful. Cases 6 and 7 were patients with lesions in the right upper lobes whose ENB biopsy specimens failed to demonstrate a malignant diagnosis (Fig 2A, B; Fig 4). After ROSE, both of these patients underwent immediate thoracoscopic wedge resections to obtain a diagnosis and then definitive surgical resection when invasive adenocarcinomas were discovered on frozen section analysis.
|
Case 9 was that of a young woman with metastatic cholangiocarcinoma who had previously undergone metastasectomy multiple times by bilateral thoracotomies. We were able to prove malignancy in a right lower lobe mass and place fiducial markers in and around this lesion to enable stereotactic radiosurgery.
We are enthusiastic for what the future holds for this emerging technology. Our own experiences are too limited thus far to draw definitive conclusions regarding its clinical utility in the workup and management of patients with thoracic malignancies. This navigation system has enabled us to reach pathology not otherwise readily accessible. The literature suggests this novel technology can be a useful diagnostic and even therapeutic tool for our patients.
We currently see the primary limitation of ENB procedures is the potential inability to navigate to the peripheral target, which may be due to no airway leading to the desired lesion or from airway compression owing to local tumor effects. The modification of preexisting bronchoscopic tools to be more applicable within the EWC may improve the diagnostic accuracy of this device. We envision, in addition to fiducial marker placement, other potential therapeutic applications of this system. We are currently developing clinical trials to best determine the utility of this technology.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Gilbert, D. O. Wilson, N. A. Christie, A. Pennathur, J. D. Luketich, R. J. Landreneau, J. M. Close, and M. J. Schuchert Endobronchial ultrasound as a diagnostic tool in patients with mediastinal lymphadenopathy. Ann. Thorac. Surg., September 1, 2009; 88(3): 896 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Rocco Invited Commentary Ann. Thorac. Surg., October 1, 2008; 86(4): 1342 - 1342. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |